These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22364316)

  • 1. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
    Castiñeiras I; Fernández-Diaz L; Juárez Y; Lueiro M
    J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
    [No Abstract]   [Full Text] [Related]  

  • 2. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
    Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
    Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ustekinumab in sub-erythrodermic psoriasis: when TNF-blockers fail.
    Buggiani G; D'Erme AM; Krysenka A; Pescitelli L; Lotti T; Prignano F
    Dermatol Ther; 2012; 25(3):283-5. PubMed ID: 22913449
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term management of erythrodermic psoriasis with anti-TNF agents.
    Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
    Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
    Lewis TG; Tuchinda C; Lim HW; Wong HK
    J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.
    Santos-Juanes J; Coto-Segura P; Mas-Vidal A; Galache Osuna C
    Br J Dermatol; 2010 May; 162(5):1144-6. PubMed ID: 20222926
    [No Abstract]   [Full Text] [Related]  

  • 7. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.
    Heikkilä H; Ranki A; Cajanus S; Karvonen SL
    Arch Dermatol; 2005 Dec; 141(12):1607-10. PubMed ID: 16365275
    [No Abstract]   [Full Text] [Related]  

  • 8. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.
    Pescitelli L; Dini V; Gisondi P; Loconsole F; Piaserico S; Piccirillo A; Stinco G; Errichetti E; Talamonti M; Tripo L; Volpi W; Prignano F
    J Dermatol Sci; 2015 May; 78(2):149-51. PubMed ID: 25681953
    [No Abstract]   [Full Text] [Related]  

  • 9. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis.
    Lisby S; Gniadecki R
    Acta Derm Venereol; 2004; 84(3):247-8. PubMed ID: 15202853
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
    Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
    Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythrodermic psoriasis and secukinumab: Our clinical experience.
    Mateu-Puchades A; Santos-Alarcón S; Martorell-Calatayud A; Pujol-Marco C; Sánchez-Carazo JL
    Dermatol Ther; 2018 Jul; 31(4):e12607. PubMed ID: 29663615
    [No Abstract]   [Full Text] [Related]  

  • 12. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab.
    Rongioletti F; Borenstein M; Kirsner R; Kerdel F
    J Dermatolog Treat; 2003 Dec; 14(4):222-5. PubMed ID: 14660268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
    Takahashi MD; Castro LG; Romiti R
    Br J Dermatol; 2007 Oct; 157(4):828-31. PubMed ID: 17711530
    [No Abstract]   [Full Text] [Related]  

  • 14. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.
    Downs AM
    Br J Dermatol; 2010 Aug; 163(2):433-4. PubMed ID: 20456344
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis.
    Dogra S; Bishnoi A; Narang T; Handa S
    Dermatol Ther; 2018 Jul; 31(4):e12611. PubMed ID: 29687662
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
    Sorensen EP; Fanucci KA; Saraiya A; Volf E; Au SC; Argobi Y; Mansfield R; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):893-8. PubMed ID: 26267736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of treatment strategies for erythrodermic psoriasis.
    Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
    J Dermatolog Treat; 2021 Feb; 32(1):49-55. PubMed ID: 31682547
    [No Abstract]   [Full Text] [Related]  

  • 18. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
    Rallis E; Verros CD
    Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythroderma in the era of biological therapies.
    Zattra E; Belloni Fortina A; Peserico A; Alaibac M
    Eur J Dermatol; 2012; 22(2):167-71. PubMed ID: 22321651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythrodermic psoriasis.
    Mumoli N; Vitale J; Gambaccini L; Sabatini S; Brondi B; Cei M
    QJM; 2014 Apr; 107(4):315. PubMed ID: 23764512
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.